Company news

Alnylam Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy

December 21, 2021

Alnylam Comments on FDA Approval of Leqvio®, the First siRNA (RNAi Therapeutic) Approved to Reduce LDL-C

December 21, 2021

Alnylam Publishes 3rd Annual Patient Access Philosophy Report Demonstrating Steady Access to Approved Therapies as Company Enters New Geographies

December 20, 2021

Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout

December 19, 2021

Alnylam Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease

December 19, 2021

Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1

December 13, 2021

Alnylam Ranks #1 in Boston Globe’s Top Places to Work List for 2021

December 1, 2021

Alnylam to Webcast Presentations at Upcoming Investor Conferences

November 22, 2021

Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day

November 18, 2021

Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021

November 12, 2021

Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension

November 7, 2021

Alnylam Presents Positive Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

November 4, 2021

Alnylam Named a Science Magazine Top Employer for Third Consecutive Year

October 31, 2021

Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity

October 27, 2021

Alnylam Announces Planned CEO Leadership Transition

October 27, 2021

Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

October 26, 2021

Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results

October 13, 2021

Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities

October 12, 2021

Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society

September 28, 2021

Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference

September 27, 2021

Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy

September 12, 2021

Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting

September 6, 2021

Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

August 8, 2021

Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity

August 2, 2021

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues

July 28, 2021

Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension

June 29, 2021

Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis

June 23, 2021

Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting

June 6, 2021

Alnylam Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy

May 31, 2021

Alnylam Announces New Advances in ATTR Amyloidosis Program

May 10, 2021

Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)

May 2, 2021

Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity

April 28, 2021

Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran

April 18, 2021

Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results

April 14, 2021

Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension

April 10, 2021

Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference

April 5, 2021

Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine

March 30, 2021

Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021

March 22, 2021

Alnylam Issues Inaugural Corporate Responsibility Summary

March 10, 2021

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity

February 10, 2021

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results

January 27, 2021

Alnylam Launches “Alnylam P⁵x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years

January 9, 2021

Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

January 6, 2021

Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders

December 20, 2020

Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day

December 14, 2020

Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies

December 6, 2020

Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1

December 2, 2020

Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. Payers

November 23, 2020

Alnylam Receives Approval for OXLUMO™ (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups

November 18, 2020

Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension

November 12, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 89 decks. Every deck is listed under its year.